September 7–8, 2018 Kyoto Hotel Okura Kyoto, Japan6. The prevalence of liver, biliary tract and...

Program

P212

1-7

/201

8/6

00

Stü

Organized by: Co-Sponsored by:

FALK FOUNDATION e.V.Leinenweberstr. 579108 FreiburgGermany

Congress DepartmentTel.: +49–761–1514–125Fax: +49–761–1514–359E-Mail: symposia@falk-foundation-symposia.orgwww.falk-foundation-symposia.org

Symposium 212

IBD and Liver: East Meets West

September 7–8, 2018Kyoto Hotel OkuraKyoto, Japan

CME credits 12

Awarded with

17811_Falk_Kyoto_Symp_212_Prog_UG.indd 1 30.07.18 10:19

3

Preface . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4

Scientific Program . . . . . . . . . . . . . . . . . . . . . . . . . 6

Posters . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10

List of Speakers, Moderators and Scientific Organizers . . . . . . . . . . . . . . . . . . . . . . . 28

Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33

12 credit hours (CME) have been awarded for the Symposium 212 by the European Union of Medical Specialists (UEMS) .

17811_Falk_Kyoto_Symp_212_Prog_Inhalt.indd 3 30.07.18 10:28

4

PrefaceWe, the organizing committee, are pleased to invite you all to the “IBD and Liver: East Meets West” Symposium that will take place in Kyoto, Japan .

This symposium will focus on inflammatory bowel diseases (IBD) and hepatitis, including nonalcoholic steatohepatitis (NASH), with additional attention on basic research fields, such as intestinal bacterial flora and regenerative medicine . It is a great pleasure to have the opportunity to hold a Falk symposium in Japan for the first time since its establishment half a century ago in 1967 . It is also a great honor for us to serve as the organizers of such an esteemed event .

As the subtitle of Symposium 212 “East meets West” suggests, we have organized the program with the belief that it is important to boost exchanges between Japan and the West, or Europe and the United States, in the fields of gastroenterology and hepatology .

IBD have conventionally been considered prevalent mostly in the West; however, their incidence is markedly rising in Japan and other Asian countries, with the current number of IBD patients exceeding 200,000 in Japan alone . In the field of hepatology, as you know, groundbreaking advancements have been made in the treatment of hepatitis C . It is no less noteworthy that many research projects, as on NASH and autoimmune hepatitis, are underway both in the East and the West .

Our program will therefore highlight IBDs and hepatitis, including NASH, areas where remarkable progress is being made, as well as basic research fields, such as intestinal bacterial flora and regenerative medicine . As world-leading gastroenterologists and hepatologists from Europe and the United States meet with Japanese experts in these fields who are receiving worldwide attention, we intend to have all participants engage in active discussions on the topics with the differences and similarities between the East and the West in mind, thereby promoting their scientific and goodwill exchanges . Furthermore, to get as many young leaders of the next generation involved in this event as possible, we have invited them to a poster session .

It is our sincere hope that all participants in this symposium, which is made possible by full support from the Falk Foundation, will make the most of the occasion as a forum for presenting and examining the latest findings from the East and the West . Through new insights and greater recognition thus obtained, the participants will gain a better understanding of the pathophysiology of these diseases to guide them toward more precise and higher-quality treatment or clinical research .

We look forward to seeing you in Kyoto with our heartfelt hospitality, or omotenashi, in this ancient capital of the East .

Toshifumi Hibi Tadakazu Hisamatsu Michio Imawari Gerhard Rogler Herbert Tilg


5

Symposium 212



Start of Registration:Thursday, September 6, 201816 .00 – 21 .00 hat the congress office

Setting Up of Poster Session:Thursday, September 6, 201816 .00 – 21 .00 h

Congress Venue:Kyoto Hotel OkuraKawaramachi-OikeNakagyo-kuKyoto 604-8558Japan

Symposium 212 is organized by Falk Foundation e.V.

Scientific Organization:Prof . Dr . Toshifumi HibiDept . of Internal MedicineKitaso Institute HospitalKitaso University5-9-1 Shirokane, Minato-kuTokyo 108-8642JapanTelephone: +81-3-5791-6487Telefax: +81-3-5791-6489E-mail: thibi@insti .kitasato-u .ac .jp

Scientific Co-Organization:T . Hisamatsu, Tokyo (Japan)M . Imawari, Kanagawa (Japan)G . Rogler, Zurich (Switzerland)H . Tilg, Innsbruck (Austria)

Official Language:English .Simultaneous translation into Japanese .


6

Friday, September 7, 2018

8.30 Welcome T . Hibi, Tokyo

8.40 State-of-the-Art Lecture: M . Watanabe, Regeneration of intestinal epithelial cells and IBD Tokyo

Session I Optimization of clinical practice in IBD: What can we learn from differences between Asian and Western countries?

Chair: S . Schreiber, Kiel; Y . Suzuki, Chiba

9.20 Epidemiology - Trends in inflammatory bowel disease S .C . Ng, in Asia Hong Kong

9.40 The best way of using anti-TNF and immunomodulators T . Matsumoto, considering the Asian-specific situation Iwate

10.00 New strategy in the surveillance colonoscopy for K . Hata, colitis cancer Tokyo

10.20 Fecal biomarkers, potential and limitations M . Allez, Paris

10.40 Coffee break with poster session

Session II Personalized health care in special situations in IBD

Chair: K . Okazaki, Osaka; C .J . van der Woude, Rotterdam

11.10 Very early onset IBD D . Graham, Cambridge

11.30 IBD in elderly patients C .N . Bernstein, Winnipeg

11.50 Pregnancy in inflammatory bowel disease U . Mahadevan, San Francisco

12.10 Gender issues in inflammatory bowel disease C .J . van der Woude, Rotterdam

12.30 Lunch break with poster session


7

Friday, September 7, 2018 Session III

Optimization of IBD treatment Chair: H . Nakase, Sapporo; G . Rogler, Zurich

14.00 Predictors of low adherence to therapy in patients C . Selinger, with IBD Leeds

14.20 Risk management in thiopurine therapy F . Hoentjen, Nijmegen

14.40 Therapeutic drug monitoring (TDM): Its role in M . Ferrante, anti-TNF therapy Leuven

15.00 Post-operative management of Crohn‘s disease patients D . Sorrentino, Roanoke


Session IV Mechanism-based treatment strategy for IBD: How to use new medicines properly

Chair: T . Hisamatsu, Tokyo; G . Rogler, Zurich

15.50 IBD pathogenesis and novel therapeutic targets G . Rogler, Zurich

16.10 Anti-TNF and cytokine inhibitors M .F . Neurath, Erlangen

16.30 Use of inhibitors of cellular adhesion molecules and A . Sharara, leukocyte trafficking in IBD Beirut

16.50 JAK inhibitors T . Kobayashi, Tokyo

17.10 Summary of the day E .M . El-Omar, Sydney

17.25 Scientific discussion with snacks


8

Saturday, September 8, 2018 Session V

Gut flora and metabolism in human health care and diseases

Chair: A . Andoh, Shiga; M .F . Neurath, Erlangen

8.30 The impact of intestinal epithelial barrier function K . Takeda, Osaka

8.50 The impact of gut luminal metabolism in health and S . Fukuda, disease Yamagata

9.10 Impact of smoking on the gut microbiota in IBD patients H . Ohno, Kanagawa

9.30 The role of diet and small bowel microbiota in health E .B . Chang, and metabolic diseases Chicago

9.50 Obesity and cellular senescence: E . Hara, A gut microbial connection Osaka


Session VI NAFLD

Chair: T . Okanoue, Osaka; H . Tilg, Innsbruck

10.40 Pathogenesis of NAFLD H . Tilg, Innsbruck

11.00 The role of the microbiome in the pathogenesis A . Nakajima, of NAFLD Kanagawa

11.20 Non-invasive assessment of fibrosis in NAFLD R . Loomba, La Jolla

11.40 Current and future treatment strategies of Z .M . Younossi, non-alcoholic steatohepatitis Falls Church

12.00 Presentation of Poster Awards T . Hisamatsu, Tokyo

12.15 Lunch break with poster session


9

Saturday, September 8, 2018 Session VII

Viral hepatitis Chair: K . Koike, Tokyo; J .-M . Pawlotsky, Paris

13.30 Innate and adaptive immunity in hepatitis B and hepatitis C T . Kanto, virus infection - Aiming at the virus elimination by 2030 Chiba

13.50 Current treatment of hepatitis B H .L .Y . Chan, Hong Kong

14.10 Hepatitis C therapy: Everything solved? J .-M . Pawlotsky, Paris

14.30 Hepatitis E: The new epidemic? H . Okamoto, Tochigi


Session VIII Autoimmune liver diseases

Chair: T .H . Karlsen, Oslo; H . Takikawa, Tokyo

15.20 Clinical management of PBC Y . Ueno, Yamagata

15.40 Autoimmune Hepatitis (AIH) A . Tanaka, Tokyo

16.10 PSC: From genes to therapy T .H . Karlsen, Oslo

16.30 IgG4-related sclerosing cholangitis H . Hamano, Nagano

16.50 Closing remarks M . Imawari, Kanagawa


10

Poster Session

IBD1. IL-33delaysrecoveryofinflammationviadown-regulationofhomeostatic

colonic ABCG5/8 Y.Mishima,H.Sonoyama,S.Ishihara,N.Oshima,I.Moriyama,K.Kawashima,Y.Kinoshita(Izumo,JP)

2. ReductionofinfliximabtreatmentafterdoseescalationinpatientswithCrohn’sdisease S.Arimitsu,H.Ito(Osaka,JP)

3. Effectivenessandassociatedprognosticfactorsofgranulocyteandmonocyteadsorptiveapheresisforpatientswithulcerativecolitis M.Miyakawa,K.Sugiyama,M.Nasuno,H.Tanaka,S.Motoya(Sapporo,JP)

4. Inadditiontotheadenocancerevents,theriskofneuroendocrinetumor(NET)developmentisincreasedinpatientswithCrohn’sdisease M.Basaranoglu,M.Kapishydag,E.Kunduz(Istanbul,TR)

5. RetrogradecontraststudyandSES-CDthroughdouble-balloonenteroscopycanpredicttheriskofbowelresectionsinCrohn’sdiseasepatientswithsmallintestinalstrictures T.Inokuchi,S.Hiraoka,N.Okazaki,E.Yasutomi,S.Oka,Y.Yamasaki, Y.Sugihara,M.Takahara,K.Harada,S.Kawano,H.Okada,J.Kato(Okayama,Tokyo,JP)

6. Theprevalenceofliver,biliarytractandpancreasabnormalitiesbyultrasoundandthenconfinedbyEUSin835patientswithinflammatoryboweldisease M.Basaranoglu(Istanbul,TR)

7. Treatmentadherenceofpatientswithinflammatoryboweldiseaseisdependentontheformof5-aminosalicylicacid N.Shoko,M.Sasaki,M.Mizuno,T.Sugiyama,Y.Yamaguchi,M.Tamura, S.Izawa,Y.Hijikata,M.Ebi,N.Ogasawara,Y.Funaki,K.Kasugai(Nagakute,JP)

8. Proton-pumpinhibitorsassociatedwithamarkedlyincreasedriskofmicroscopiccolitis O.K.Bonderup,G.L.Nielsen,M.Dall,A.Pottergaard,J.Hallas(Silkeborg,Aalborg,Odense,DK)

9. AssociationsbetweenthePrognosticNutritionalIndexandmorbidity/mortalityduringintestinalresectioninpatientswithulcerativecolitis T.Chohno,M.Uchino,T.Minagawa,R.Kuwahara,Y.Horio,H.Sasaki, T.Bando,H.Ikeuchi(Nishinomiya,JP)

10.* Crohn’sdiseasepatient-derivedsmallintestinalorganoidsrevealdisease-statusrelatedmodificationofstemcellproperties K.Suzuki,J.Takahashi,Y.Hiraguri,S.Yui,H.Shimizu,K.Tsuchiya, T.Nakamura,K.Ohtsuka,R.Okamoto,M.Watanabe(Tokyo,JP)


11

11. EffectofaHibiscussabdariffaextractinliverinflammationandintestinalepithelialpermeabilityinobesemice P.Diez-Echave,T.Vezza,L.Hidalgo-Garcia,J.Garrido-Mesa,S.Pimentel-Moral,A.Segura-Carretero,M.E.Rodriguez-Cabezas,J.Galvez(Granada,ES)

12. Analyzingpsychologicalstructureofpatientswithinflammatoryboweldiseaseandmedicalstaffforbetterpatientrelations A.Morimoto,H.Ito(Osaka,JP)

13. Anovelsmall-caliberdeepenteroscopecanovercometechnicaldifficultyofballoondilatationforstrictureinpatientswithCrohn‘sdisease Y.Endo,A.Yoshida,S.Hara,S.Umezawa,Y.Morikawa,F.Ueno(Kamakura,JP)

14. Relationshipbetweenendoscopicmucosalhealingandhistologicinflammationduringremissionmaintenancephaseinulcerativecolitis M.Kanazawa,F.Takahashi,K.Tominaga,K.Abe,N.Izawa,K.Fukushi, K.Nagashima,A.Kanamori,K.Takenaka,T.Sugaya,A.Takada,Y.Imai, H.Hiraishi,A.Irisawa(Tochigi,JP)

15. Anastomoticulcerationinpatientsaftersmallbowelresection:Crohn‘sdisease,bacterialovergrowthor...what? E.Fedorov,E.Ivanova,E.Tikhomirova,K.Bolikhov,O.Yudin(Moscow,RU)

16. DetectionofgutdysbiosisduetoreducedClostridiumsubclusterXIVabasedontheserumbileacidprofile M.Murakami,J.Iwamoto,A.Honda,T.Miyazaki,T.Ikegami,Y.Matsuzaki(Ibaraki,JP)

17.* Heme-inducedSpi-CinmacrophagespreventscolitisbyinhibitingexpressionofNF-kappaB/IRF5-dependentgenes H.Kayama,M.Kohyama,H.Arase,T.Kaisho,K.Takeda(Suita,Wakayama,JP)

18. Probiotic-derivedsuper-long-chainpolyphosphateinducesmucosalhealinginpatientswithrefractoryulcerativecolitis M.Fujiya,N.Ueno,S.Kashima,K.Tanaka,A.Sakatani,K.Moriichi,H.Konishi,T.Okumura(Asahikawa,JP)

19. EffectivenessofMultiMatrixSystemmesalazinefortheinductionofremissioninpatientswithulcerativecolitiswhoinsufficientlyrespondtoothermesalazineformulations:AJapanesesingle-centerstudy H.Tanaka,K.Sugiyama,M.Miyakawa,M.Nasuno,S.Motoya(Sapporo,JP)

20. TheefficacyofinfliximabtreatmentafterthesurgicaltreatmentofperianalfistulainCrohn’sdiseasepatients S.Furukawa,T.Yamana,R.Sahara(Tokyo,JP)

21. Short-andlong-termoutcomesofinfliximabtreatmentforpatientswithulcerativecolitisandassociatedprognosticfactors M.Nasuno,K.Sugiyama,M.Miyakawa,H.Tanaka,S.Motoya(Sapporo,JP)

22. Long-termclinicalstudyofperianallesionswithCrohn’sdisease K.Futami,D.Higashi,Y.Hirano(Fukuoka,JP)


12

23.* Protectiveeffectofautophagyonendoplasmicreticulumstress-inducedapoptosisofintestinalepithelialcellsinchroniccolitismodel A.Nishida,K.Nishino,K.Takahashi,S.Bamba,A.Andoh(Otsu,JP)

24. TheimmunomodulatoryandantimicrobialpropertiesofPTSOcontributetoitsintestinalanti-inflammatoryeffectinexperimentalcolitis J.Galvez,T.Vezza,F.Algieri,J.Garrido-Mesa,A.Rodriguez-Nogales, A.Banos,F.Garcia,M.P.Utrilla,M.E.Rodriguez-Cabezas(Granada,ES)

25. Hospital-basedIBDepidemiologicaltrendsinaRomaniantertiaryreferralcenter C.Gheorghe,R.Iacob,B.Stoica,C.Purice,S.Iacob,R.Vadan,A.Dimitriu,S.Ichim,M.Cojocaru,A.Saizu,A.Les,A.Stefan,M.Diculescu,L.S.Gheorghe(Bucharest,RO)

26. Elevatedriskofstomaoutletobstructionfollowingcolorectalsurgeryinpatientsundergoingilealpouch-analanastomosis S.Okada,K.Hata,S.Emoto,K.Murono,M.Hiyoshi,M.Kaneko,K.Sasaki,Y.Shuno,T.Nishikawa,T.Tanaka,K.Kawai,H.Nozawa(Tokyo,JP)

27. LaparoscopycombinedwithenhancedrecoverypathwayinileocecalresectionforCrohn’sdisease:Arandomizedstudy W.Liu,Y.Zhu,W.Zhou,Q.Cao(Hangzhou,CN)

28. KeystohavinganormalpregnancyanddeliveryinIBDpatients C.Gheorghe,A.Dimitriu,S.Morogan,L.S.Gheorghe(Bucharest,RO)

29. Importanceofthefindingsofrectalsparingforthedecisionofseverityofulcerativecolitis M.Takasaki,Y.Oki,M.Hashiba,H.Mizuta,T.Yamada,M.Ono,T.Saibara(Nankoku,JP)

30. Infliximabbiosimilarinthetreatmentofulcerativecolitis:AJapanesesinglecohortobservationalstudy S.Hamanaka,T.Nakagawa,T.Oike,Y.Yokoyama,Y.Imai,N.Akizue, K.Ishikawa,Y.Ohta,T.Taida,K.Okimoto,K.Saito,D.Maruoka,T.Matsumura,M.Arai,T.Katsuno,N.Kato(Ichikawa,Chiba,JP)

31. CorrelationbetweenmacroscopicseverityofCrohn‘sdiseaseinresectedintestineandbowelwallthicknessasevaluatedbywater-immersionultraso-nography K.Yaguchi,T.Sasaki,T.Mitsui,Y.Tamura,Y.Hashimoto,Y.Ikeda, T.Ogashiwa,A.Fujii,M.Izumi,A.Hanzawa,N.Shibata,H.Yonezawa, K.Numata,S.Maeda,H.Kimura,R.Kunisaki(Yokohama,JP)

32. Effectsofacesulfamepotassiumonindomethacin-inducedenteritis Y.Hanawa,M.Higasiyama,R.Hokari,K.Inaba,N.Sugihara,A.Wada, K.Horiuchi,H.Huruhashi,T.Takazyo,N.Shibuya,Y.Okada,C.Kurihara, C.Watanabe,S.Komoto,K.Tomita,S.Nagao,(Tokorozawa,JP)


13

33.* Developmentofanoveltransabdominalultrasounddiseaseactivityscoreinpatientswithulcerativecolitis(UCUSscore) Y.Hashimoto,N.Kume,T.Mitsui,A.Ikeda,Y.Tamura,T.Ogashiwa, M.Izumi,A.Hanzawa,H.Yonezawa,Y.Saigusa,S.Maeda,H.Kimura, R.Kunisaki(Yokohama,JP)

34.* Clinicopathologicalfeaturesofnivolumab-inducedcolitis S.Yanai,K.Kawasaki,S.Nakamura,Y.Toya,K.Ishida,T.Sugai,T.Matsumoto(Morioka,JP)

35. Berberinechloride,anenhancerofIL-10productioninmacrophages,ameliorateanexperimentalcolitisinmice S.Hayashi,N.Wakabayashi,Y.Ogawa,M.Kadowaki(Toyama,JP)

36. Correlationbetweenfascin-1andcaspase-8proteinsexpressionsinulcerativecolitis A.Pryczynicz,P.Kuczynska,J.Zinczuk,K.Zareba,W.Ustymowicz, M.Maciorkowska,L.Zakrzewski,E.Maciorkowska,K.Guzinska-Ustymowicz(Bialystok,PL)

37. IL-4receptor-deficientmiceareresistanttothedevelopmentofDSS-inducedcolitis A.Hertati,S.Hayashi,M.Kadowaki(Toyama,JP)

38.* Luminalproteaseactivityisincreasedinpouchinflammationofulcerativecolitispatients N.Maharshak,I.C.Carroll,H.Toulchinsky,I.Dotan,S.Hoffman(TelAviv,PetahTikva,IL;ChapelHill,US)

39. Intestinalanti-inflammatoryeffectsofKalanchoebrasiliensisandKalanchoepinnataextractsexertintestinalanti-inflammatoryeffectsinexperimentalcolitis L.Hidalgo-Garcia,J.A.Molina-Tijeras,P.Diez-Echave,A.Ruiz-Malagon,A.W.Lopes,S.M.Zucolotto,G.Coelho,M.E.Rodriguez-Cabezas,J.Galvez(Granada,ES;Natal,BR)

40. Accuracyoftransabdominalultrasoundinassessingdiseaseactivityinulcerativecolitis S.Sagami,T.Kobayashi,T.Kanazawa,K.Aihara,H.Morikubo,M.Matsubayashi,A.Fuchigami,H.Kiyohara,R.Ozaki,S.Okabayashi,M.Nakano,T.Hibi(Tokyo,JP)

41. Clinicalusefulnessofbowelultrasonographyforpatientswithulcerativecolitis K.Matsumoto,S.Niida,H.Shimazaki,K.Sugiyama,M.Miyakawa, M.Nasuno,H.Tanaka,S.Motoya(Sapporo,Engaru,JP)

42. TNF-αandIFN-γinduceananti-inflammatoryphenotypeinintestinalmesenchymalstromalcells L.Hidalgo-Garcia,M.E.Rodriguez-Cabezas,J.A.Molina-Tijeras,T.Vezza,P.Diez-Echave,A.J.Ruiz-Malagon,F.Huertas,P.Becerra-Massare,J.Galvez,P.Anderson(Granada,ES)


14

43. Acomparisonofthiopurinesversusanti-TNF-αtherapyinsteroid-dependentulcerativecolitisusingpropensity-scorematchedanalysis S.Hosomi,M.Ohira,H.Yamagami,R.Nakata,N.Sugita,Y.Nishida,S.Itani,T.Yukawa,N.Kamata,K.Otani,Y.Nagami,F.Tanaka,K.Taira,T.Tanigawa,T.Watanabe,Y.Fujiwara(Osaka,JP)

44. Ontheclinicalcourseofanti-TNFαagentinulcerativecolitis(UC) E.Saito,K.Matsuoka,T.Fujii,M.Nagahori,K.Ohtsuka,M.Watanabe(Tokyo,JP)

45. Shareddecisionmakingwasimportantinlowadherentinflammatoryboweldiseasepatientstomesalazinetablets A.Ishibashi,S.Kato,K.Kani,M.Oka,T.Michida,S.Nagoshi,K.Yakabi(Kawagoe,JP)

46.* Ral-NLRP3inflammasomepathwaypromotescolitis-associatedcancer T.Iida,N.Minami,H.Horiuchi,H.Nakase(Sapporo,Kyoto,Sendai,JP)

47. Short-andlong-termefficacyof5-aminosalicylicacidforintestinalBehçetdisease A.Ikeda,H.Nishioka,T.Mitsui,Y.Tamura,Y.Hashimoto,T.Ogashiwa, A.Fujii,T.Sasaki,H.Kinoshita,K.Ikoma,Y.Sameshima,H.Ohi,H.Kimura,R.Kunisaki(Yokohama,Kagoshima,JP)

48. Identificationofcolitis-associatedbacteriainintestineofinflammatoryboweldiseasepatients J.Seishima,N.Iida,S.Kaneko(Kanazawa,JP)

49. Crohn‘sdiseasepatientswiththeanallesionasaninitialsymptomunder-goingourhospitaltreatment Y.Shibata(Toyohashi,JP)

50. ClinicalusefulnessofbowelultrasonographyforcoloniclesioninCrohn’sdisease H.Shimazaki,S.Niida,K.Matsumoto,K.Sugiyama,M.Miyakawa,M.Nasuno,H.Tanaka,S.Motoya(Engaru,Sapporo,JP)

51. Clinicalfeaturesandlong-termprognosisofintestinalBehçet‘sdiseaseaftersurgery I.Ise,K.Watanabe,H.Suzuki,H.Karasawa,A.Kohyama,N.Tanaka, S.Ohnuma,H.Musha,F.Motoi,T.Kamei,T.Naitoh,M.Unno(Sendai,JP)

52. AntimicrobialpeptidesindifferentphenotypesofCrohn‘sdiseaseinchildren A.Wedrychowicz,P.Tomasik,K.Kowalska-Duplaga,S.Pieczarkowski, K.Fyderek(Krakow,PL)

53. TherapeuticefficacyofanelementaldietforpatientswithCrohn’sdiseaseanditsassociationwithaminoacidmetabolism T.Sugaya,M.Nakano,F.Takahashi,K.Takenaka,K.Tsuchida,K.Tominaga,T.Murohisa,M.Iijima,A.Irisawa(Tochigi,JP)

54. CapsuleenteroscopyindiagnosisofisolatedsmallbowelCrohn‘sdisease E.V.Ivanova,E.Fedorov,L.Mikhaleva,E.Tikhomirova(Moscow,RU)


15

55. Diagnosticgastrointestinalultrasoundexamination(GIUS)inpatientswithinflammatoryboweldisease(IBD)–TheNewZealandexperience R.Lubcke,M.Pickles(Dunedin,NZ)

56. FecalcalprotectinpredictsdiseaseactivityofCrohn’sdiseaseevaluatedbyballoon-assistedendoscopy F.Iwamoto,K.Matsuoka,M.Motobayashi,K.Takenaka,T.Fujii,E.Saito, M.Nagahori,T.Sato,K.Ohtsuka,N.Enomoto,M.Watanabe(Yamanashi,JP)

57. TreatmentoutcomeofthiopurinesinpatientswithulcerativecolitiswhowereheterozygousforNUDT15R139C(C/T) T.Takagawa,Y.Kakuta,A.Fujimori,K.Kojima,R.Koshiba,K.Fujimoto, T.Sato,M.Kawai,K.Kamikozuru,Y.Yokoyama,T.Miyazaki,N.Hida, K.Watanabe,K.Hori,H.Ikeuchi,S.Nakamura(Nishinomiya,Sendai,JP)

58. Berberineimprovedexperimentalchroniccolitisviaregulatinginterferon-γproductivelaminapropriaCD4+TcellsthroughAMPKactivation M.Takahara,A.Takaki,S.Hiraoka,H.Okada(Okayama,JP)

59. Treatmentoutcomeofpouch-relatedcomplicationsafterileo-analanasto-mosisinulcerativecolitis K.Takahashi,S.Haneda,Y.Funayama(Sendai,JP)

60. Theadditionalvalueofcytapheresistherapyinpatientswithsevereulcerativecolitistreatedwithoraltacrolimus S.Takahashi,M.Colvin,T.Kagawa,Y.Aoyama,M.Matsueda,Y.Kawai, K.Okamoto,I.Sakakihara,K.Izumikawa,K.Yamamoto,S.Tanaka, M.Matsuura,S.Ishikawa,M.Wato,T.Hasui,T.Inaba(Takamatsu,JP)

61. Propertimingofhumanadipose-derivedmesenchymalstemcell(hAdMSC)injectionamelioratesdextransulfatesodium(DSS)-inducedcolitisinmicethroughtheinductionofM2macrophagesandregulatoryTcells Y.Kawata,A.Tsuchiya,J.Yokoyama,S.Terai(Niigata,JP)

62. SmallbowelmucosalhealingofCrohn’sdiseasetreatedwithanti-TNFantibodies K.Takenaka,K.Ohtsuka,T.Fujii,M.Nagahori,E.Saito,M.Motobayashi, K.Suzuki,M.Watanabe(Tokyo,JP)

63. Theair-enemaimageofultra-lowdoseCTcolonographycanbeanalternativediagnostictechniquefortheassessmentofmucosalhealinginthepatientswithulcerativecolitis K.Takeuchi,A.Yamada,Y.Suzuki,K.Matsuoka(Sakura,JP)

64. QingChangHuaShigranulecontributestothebalanceofTh17/TreginTNBS-inducedcolitis K.Zheng,J.Jia,H.Shen(Nanjing,CN)

65. MeasurementofserumtroughlevelsofinfliximabisusefulinpatientswithCrohn‘sdiseaseineffectivetoinfliximabtreatment:Asinglecenterstudy T.Kinjo,A.Iraha,A.Hokama(Nishihara,JP)


16

66. Clinicalcharacteristicsandoutcomesof5-ASAintoleranceinpatientswithulcerativecolitis H.Kiyohara,T.Kobayashi,T.Hibi(Tokyo,JP)

67. PreoperativeoralantibioticprophylaxisforthepreventionofsurgicalsiteinfectionsinpatientswithCrohn‘sdisease M.Uchino,H.Ikeuchi,T.Bando,T.Chohno,H.Sasaki,Y.Horio,R.Kuwahara,T.Minagawa,Y.Takesue(Hyogo,JP)

68. Theutilityasabiomarkeroffecalcalprotectinforpredictingtheclinicaloutcomeofgranulocyteandmonocyteadsorptiveapheresistreatmentinpatientswithulcerativecolitis N.Ueno,Y.Kobayashi,Y.Murakami,T.Iwama,T.Kunogi,K.Takahasi,K.Ando,S.Kashima,K.Moriichi,H.Tanabe,M.Fujiya,T.Okumura(Asahikawa,JP)

69. Dietarymedium-chaintriglyceridespreventchemicallyinducedexperimentalcolitisinrats H.Kono,K.Ishii,N.Hosomura,M.Ogiku,D.Ichakawa(Yamanashi,JP)

70. Impactofanoliveleafextractonintestinalpermeabilityandliverinflammationinamousemodelofdiet-inducedobesity T.Vezza,A.Rodriguez-Nogales,F.Algieri,J.Garrido-Mesa,B.Martin-Garcia,A.Segura-Carretero,V.Micol,M.P.Utria,M.E.Rodriguez-Cabezas,J.Galvez(Granada,Elche,ES)

71. ClinicalefficacyofGMAinelderlypatientswithulcerativecolitisisassociatedwithmucosalexpressionofMIP-1βandIL23 C.Kurihara,T.Ohmori,T.Inaba,N.Sugihara,Y.Hanawa,K.Horiuchi,A.Wada,H.Furuhashi,T.Takajo,Y.Okada,N.Shibuya,M.Higashiyama,C.Watanabe,S.Komoto,K.Tomita,S.Miura,R.Hokari(Tokyo,Ageo,Tokorozawa,JP)

72.* Non-adherenceofIBDmedicationsanddiseaseactivityduringpregnancyandpregnancyoutcomes C.Watanabe,R.Hokari(Tokorozawa,JP)

73. ClinicalfeaturesofanorectalcancerinCrohn’sdisease K.Watanabe,A.Kohyama,H.Suzuki,H.Karasawa,N.Tanaka,S.Ohnuma,H.Musha,F.Motoi,T.Kamei,T.Naitoh,M.Unno(Sendai,JP)

74. Anti-inflammatorypropertiesofoligosaccharidesderivedfromCynarascolymusinDSS-inducedcolitisinmice J.A.Molina-Tijeras,L.Hidalgo-Garcia,P.Diez-Echave,A.Ruiz-Malagon, T.Vezza,N.Munoz-Almagro,C.Sabater,M.E.Rodriguez-Cabezas, J.Galvez,M.P.Utrilla(Granada,Madrid,ES)

75. EffectsofquercetinloadedsilkfibroinnanoparticlesinDSSexperimentalcolitisinmice M.D.Lorente,P.Diez-Echave,T.Vezza,A.Ruiz-Malagon,J.A.Molina-Tijeras,L.Hidalgo-Garcia,M.E.Rodriguez-Cabezas,A.Lozano-Perez,J.L.Cenis,J.Galvez(Granada,Murcia,ES)


17

76. MedicationadherencetothiopurinesisimprovedbynursinginterventionforIBDoutpatients:Asinglecenterprospectivestudy M.Okuda,K.Sakagami,M.Matsumoto,H.Ito,S.Shinzaki(Osaka,Suita,JP)

77. Theeffectofrebamipide,sucralfateandrifaximinonradiation-inducedintestinalepithelialbarrierinjury W.Moon,K.I.Seo(Busan,KR)

78. EvaluationofCD11c-,CD123-andCD68-positivecellsinthecolonicmembraneofchildrenwithCrohn’sdisease M.Maciorkowska,M.Zakrzewski,W.Ustymowicz,I.Roszko-Kirpsza, B.Kaminska,A.Szlagatys-Sidorkiewicz,K.Guzinska-Ustymowicz, A.Pryczynicz,J.Zinczuk,E.Maciorkowska(Bialystok,Gdansk,PL)

79. Thechangeofbonemineraldensityinpatientswithinflammatoryboweldisease W.Moon,K.I.Seo(Busan,KR)

80. ClinicalassessmentofcasesofintestinalBehçetdiseasetreatedwithanti-TNF-αantibodyatourhospital Y.Ando,T.Sakurai,H.Miyashita,Y.Akita,M.Hachiya,Y.Maruyama, R.Miyazaki,Y.Nagata,R.Sawada,J.Mitobe,M.Mitsunaga,T.Yamasaki,T.Kato,M.Saruta(Tokyo,JP)

81. InflammatoryinfiltrationCD15/CD45-positivecellsandcorrelationof c-erbB-2expressioninIBD W.Ustymowicz,M.Maciorkowska,A.Pryczynicz,M.Zakrzewski,I.Hawryluk,K.Zareba,J.Zinczuk,E.Maciorkowska,K.Guzinska-Ustymowicz(Bialystok,PL)

82. Usefulnessofmeasuringseruminfliximabconcentrationsduringtreatmentwithinfliximabforulcerativecolitis K.Yokoyama,K.Kawagishi,K.Kobayashi(Sagamihara,JP)

83. Efficacyandrelatedissuesofcytapheresisinelderlypatientswithulcerativecolitis Y.Yokoyama,K.Watanabe,K.Kamikozuru,A.Fujimori,T.Sato,R.Koshiba,K.Fujimoto,M.Kawai,T.Takagawa,Y.Kita,N.Miyazaki,N.Hida,S.Nakamura(Nishinomiya,JP)

84. EvaluationofCD11c-,CD123-andCD68-positivecellsinthecolonicmucosalmembraneofchildrenwithulcerativecolitis M.Zakrzewski,M.Maciorkowska,W.Ustymowicz,I.Roszko-Kirpsza, B.Kaminska,A.Szlagatys-Sidorkiewicz,E.Maciorkowska,A.Pryczynicz, J.Zinczuk,K.Guzinska-Ustymowicz(Bialystok,Gdansk,PL)

85. StudyofsurgicalcasesofanalfistulaassociatedwithCrohn’sdisease K.Matsuda,K.Ohno,Y.Okada,T.Yagi,M.Tsukamoto,Y.Fukushima, A.Horiuchi,R.Shimada,T.Ozawa,T.Hayama,T.Tsuchiya,K.Nozawa, H.Aoyagi,A.Isono,K.Abe,S.Kodashima,T.Yamamoto,A.Tanaka, Y.Sasajima,F.Kondo,Y.Hashiguchi(Tokyo,JP)


18

86. Studyofulcerativecolitiscomplicatedbyprimarysclerosingcholangitis S.Murasugi,A.Ito,K.Yasuhiro,M.Yonezawa,T.Omori,K.Tokushige(Tokyo,JP)

87.* Theactin-bundlingproteinfascin-1isoverexpressedinulcerativecolitisandisassociatedwithCEACAM1expression J.Zinczuk,A.Pryczynicz,K.Zareba,W.Ustymowicz,M.Maciorkowska, L.Zakrzewski,A.Chabowski,K.Guzinska-Ustymowicz(Bialystok,PL)

88. ExplorationfornaturalmedicinesthatstimulatetheproductionofIL-10inintestinalmacrophagesasanoveltherapeuticapproachininflammatoryboweldisease D.Zinsou,S.Hayashi,M.Kadowaki(Toyama,JP)

89. TRPV4regulatesvascularendothelialpermeabilityduringcolonicinflamma-tionindextransulphatesodium-inducedmurinecolitis K.Matsumoto,T.Tsukahara,K.Amagase,M.Tominaga,S.Kato(Kyoto,Okazaki,JP)

90. Ustekinumab-inductionandmaintenanceeffectsinpatientswithCrohn’sdiseaseinasinglecenterstudy S.Kato,A.Ishibashi,K.Kani,M.Oka,T.Michida,S.Nagoshi,K.Yakabi(Kawagoe,JP)

91. Diagnosticandclinicalroleofserumproteinase3antineutrophilcytoplasmicantibodiesininflammatoryboweldisease H.Sakisaka,H.Takedatsu,K.Mitsuyama,S.Fukunaga,S.Yoshioka, R.Yamauchi,T.Torimura,S.Sakisaka(Fukuoka,Kurume,JP)

92. Differentinvolvementofinnateversusadaptiveimmunityindrugresistantinflammatoryboweldisease S.Okabayashi,T.Noake,T.Kinugasa,H.Himuro,T.Takeuchi,E.Mizoguchi,H.Suzuki,K.Nakano,Y.Yamada,Y.Akagi,Y.Araki,K.Mitsuyama, A.Mizoguchi(Kurume,Kawasaki,JP)

93. ExpressionofCD15/CD45-positivecellsincorrelationofapoptosisinIBDand CRC W.Ustymowicz,K.Guzinska-Ustymowicz,I.Hawryluk,A.Pryczynicz, J.Zinczuk,K.Zareba,M.Zakrzewski,M.Ustymowicz,E.Maciorkowska, M.Maciorkowska(Bialystok,PL)

94. TheeffectsofsmokingongutecosystemofpatientswithIBD E.Miyauchi,Y.Nakanishi,K.Uchiyama,S.Koido,H.Arakawa,M.Kawasumi,A.Ito,T.Ohkusa,H.Ohno(Ebina,Tokyo,JP)

95. Severityofstress-inducedintestinaldysfunctionassociateswithcharacteristicchangesinbehavioralpatternandgutmicrobiotacompositioninanexperimentalratmodel T.Takajo,K.Shimizu,H.Tsuchihashi,S.Enomoto,M.Tanichi,H.Toda, K.Tomita,N.Sugihara,A.Wada,K.Inaba,Y.Hanawa,K.Horiuchi,H.Furuhashi,M.Higashiyama,Y.Okada,C.Kurihara,C.Watanabe,S.Komoto,S.Nagao,K.Kumira,S.Miura,R.Hokari(Tokorozawa,Tokyo,JP)


19

96. RotavirusinfectioninpediatricIBDpatients I.Pukite,I.Kaze(Riga,LV)

97. Single-centerexperienceofinfliximabinJapanesechildrenwithulcerativecolitis H.Shimizu,I.Takeuchi,K.Tokita,K.Arai(Tokyo,JP)

98. Efficacyofmesalazinepowderonuppergastrointestinallesionsinvolvedininflammatoryboweldisease H.Otake,Y.Ishii,T.Kanemura,A.Haga,T.Mitsui,Y.Hashimoto,A.Ikeda,M.Nishio,T.Ogashiwa,H.Kimura,H.Mashima,R.Kunisaka(Yokohama,Saitama,JP)

99. Breathtestingforinflammatoryboweldisease G.Woodfield,I.Belluomo,G.Lin,P.Boshier,A.Romano,J.Martin, C.Groves,L.Marelli,B.Saunders,W.Atkin,G.Hanna(London,GB)

100.Theuseofvedolizumabinpreventingpostoperativerecurrenceinhigh-riskCrohn‘sdiseasepatients A.Yamada,K.Matsuoka,Y.Suzuki,Y.Komaki,F.Komaki,A.Sakuraba(Chiba,Kagoshima,JP;Chicago,US)

101. Fecalimmunochemicaltestasanalternativemonitoringmethodforcolonoscopyforulcerativecolitis T.Omori,S.Hosoya,K.Yasuhiro,H.Kambayashi,S.Murasugi,A.Ito, M.Yonezawa,K.Tokushige(Tokyo,JP)

102.ClinicalcoursesandcorrelationswithulcerativecolitisinJapanesepatientswithprimarysclerosingcholangitis T.Taida,J.Kumagai,S.Ogasawara,Y.Ohta,S.Hamanaka,K.Okimoto, K.Saito,D.Maruoka,T.Matsumura,T.Nakagawa,M.Arai,T.Katsuno, T.Tsuyuguchi,N.Kato(Chiba,JP)

103.EntericneuronsinteractwithdendriticcellsinthemousecolonicmucosabyreleasingIL-6 S.Zhang,H.Ogata,T.Yamamoto,M.Kadowaki(Toyama,JP)

104.ProtectiveroleofIL-10producingplasmablasts(Preg)incolitis A.Yano,A.Nishida,A.Andoh,E.Mizoguchi,A.Mizoguchi(Fukuoka,Shiga,JP)

105.Long-termprognosisofJapanesepatientswithbiologic-naïveCrohn’sdiseasetreatedwithanti-tumornecrosisfactor-αantibodies:Aretrospectivesingle-centercohortstudy R.Moroi,K.Endo,K.Yamamoto,T.Naito,M.Onodera,M.Kuroha, Y.Kanazawa,Y.Kakuta,A.Masamune,Y.Kinouchi,T.Shimosegawa(Sendai,JP)

106.ComprehensiveanalysistoidentifyaberrantDNAmethylationforpredictingcolitis-associatedcancerinulcerativecolitispatients Y.Toiyama,Y.Okugawa,T.Araki,M.Uchino,H.Ikeuchi,M.Kusunoki(Tsu,JP)


20

107. Lossofresponseinanti-tumornecrosisfactor-αbiologicagentsinpatientswithCrohn’sdisease:Amulticenterretrospectivestudy T.Sugiyama,S.Nakagawa,M.Kimura,R.Kondo,T.Ozeki,S.Inoue,K.Adachi,T.Yoshimine,Y.Yamaguchi,Y.Tamura,S.Izawa,Y.Hijikata,M.Ebi,M.Mizuno,S.Yamamoto,Y.Hunaki,N.Ogasawara,M.Sasaki,K.Kasugai,T.Mizoshita,M.Endo,Y.Kimura,K.S.Senoo,T.Yamada,Y.Hirata(Nagakute,Nagoya,Kawasaki,Kasugai,JP)

108.AssociationbetweengutmicrobiotaandundercarboxylatedosteocalcinwhichisanalternativeindicatorofvitaminKdeficiencyinpatientswithCrohn‘sdisease K.Wagatsuma,S.Yamada,M.Ao,M.Matsuura,H.Tsuji,T.Iida,K.Miyamoto,K.Oka,M.Takahashi,K.Tanaka,H.Nakase(Kyoto,Kobe,Sapporo,Tokyo,JP)

109.Disordersofliverfunctionininflammatoryboweldiseasesinchildren G.Volynets,A.Khavkin,A.Nikitin,T.Skvortsova,E.Nikonov(Moscow,RU)

110. ThreeboyswithXIAPdeficiencymimickingrefractoryCrohn’sdisease N.Toita,A.Kamada,S.Fujiwara,M.Takahashi,M.Konno,S.Abdrabou, Y.Tozawa,M.Ueki,S.Takezaki,M.Yamada,T.Ariga,H.Kanegane(Sapporo,Tokyo,JP)

111. InvestigationofIBDunclassifiedwithMEFVgeneanalysis D.Saito,M.Hayashida,R.Ozaki,O.Kikuchi,T.Sato,S.Tokunaga,S.Minowa,O.Ikezaki,T.Mitsui,M.Miura,A.Sakuraba,H.Nakase,T.Hisamatsu(Tokyo,Sapporo,JP)

Liver

112. TenofovirandentecavirtreatmentsdecreaserenalfunctioninchronichepatitisBpatientsinrealclinicalpractice K.I.Seo,B.C.Yun,S.U.Lee,B.H.Han,E.T.Park(Busan,KR)

113. Animbalanceoffreeaminoacidsinportalbloodinducesendoplasmicreticulum(ER)stresstohepatocytesviathesuppressionoflipidsecretioninnon-alcoholicfattyliverdisease(NAFLD) A.Sano,E.Kakazu,T.Morosawa,J.Inoue,M.Ninomiya,T.Iwata,S.Takai,T.Nakamura,T.Shimosegawa,A.Masamune(Sendai,JP)

114. Gutmicrobiotainprimarysclerosingcholangitisischaracterizedbyspecificcompositionoffungi L.Bajer,N.Galanova,M.Kostovcik,M.Kverka,K.Klimesova,J.Brezina, K.Chmelova,J.Spicak,P.Drastich(Prague,CZ)

115. HepaticsteatosisandfibrosisinpatientswithchronichepatitisC:TheeffectofS-adenosylhomocysteine E.Altintas,L.Ayaz,O.Sezgin,E.Ucbilek,L.Tamer,A.Tombak(Mersin,TR)


21

116. EffectofaMorusalbaleafextractinanexperimentalmodelofobesity:Impactonliversteatosisandinflammation A.Ruiz-Malagon,J.A.Molina-Tijeras,P.Diez-Echave,L.Hidalgo-Garcia, T.Vezza,M.E.Rodriguez-Cabezas,A.Lozano-Perez,J.L.Cenis,J.Galvez(Granada,Murcia,ES)

117. Combiningprobioticsandanangiotensin-IItype1receptorblockerhasbeneficialeffectsonhepaticfibrogenesisinaratmodelofnon-alcoholicsteatohepatitis H.Kawaratani,Y.Sawada,T.Kubo,Y.Fujinaga,M.Furukawa,S.Saikawa,S.Sato,K.Seki,H.Takaya,Y.Okura,K.Kaji,N.Shimozato,M.Kitade, K.Moriya,T.Namisaki,T.Akahane,A.Mitoro,H.Yoshiji(Nara,JP)

118. HBVpatientswiththeHBeAgnegative/lowHBsAg/highHBcrAghaveahighriskofHBV-relatedHCC Y.Suzuki,S.Maekawa,F.Iwamoto,M.Sato,N.Enomoto(Yamanashi,JP)

119. Treatmentofhepatocellularcarcinomausing2-deoxy-D-glucoseencapsulatedinPLGAnanoparticlesinmice K.Sasaki,S.Nishina,Y.Hara,H.Ikemoto,K.Fukuda,K.Hino(Kurashiki,Hakata,JP)

120.Occurrence/recurrenceofhepatocellularcarcinomaaftereradicationofhepatitisCviruswithIFN-freeDAAtherapy M.Sato(Yamanashi,JP)

121. TheinfluenceofMTHFRgenepolymorphismonthelong-termcourseinG1hepatitisCpatientswhoareachievedsustainedviralresponsetreatedwithpegylatedinterferonplusribavirin Z.Altintas,I.Yilmaz,H.Celik,E.Ucbilek,S.Yaras,O.Ozdogan,F.Ates, O.Sezgin,E.Altintas(Mersin,TR)

122.Astudyontheusefulnessofserinepalmitoyltransferaselongchainsubunit3(SPTLC3)inNAFLD-relatedhepatocarcinogenesis S.Ijuin,K.Oda,T.Tamai,S.Mawatari,S.Tashima,A.Kasai,K.Tabu, K.Kumagai,A.Moriuchi,H.Uto,A.Ido(Kagoshima,Miyazaki,JP)

123.Therelationshipbetweenserumalbuminandplasma-branchedchainaminoacids(pBCAAs)inrecentchronicliverdisease:Asingle-centerretrospectivestudy E.Kakazu,A.Sano,T.Morosawa,J.Inoue,M.Ninomiya,T.Iwata,S.Takai,T.Nakamura,T.Shimosegawa,A.Masamune(Sendai,JP)

124.*Chitinase3-like1exacerbatesliverfibrosisbyenhancingintrahepaticaccumulationandactivationofmacrophagesinmice M.Higashiyama,K.Tomita,H.Nakashima,H.Furuhashi,N.Sugihara, T.Takajo,C.Kurihara,K.Shirakabe,Y.Okada,K.Horiuchi,A.Wada, K.Inaba,Y.Hanawa,C.Watanabe,S.Komoto,S.Nagao,S.Miura, R.Hokari(Tokorozawa,JP)


22

125.Oraladministrationoffructoseexacerbatesliverfibrosisandhepatocarcino-genesisviaincreasedintestinalpermeabilityinaratsteatohepatitismodel K.Seki,M.Kitade,K.Kaji,T.Namisaki,K.Moriya,K.Nakanishi,Y.Tsuji, H.Yoshiji(Kashihara,JP)

126.*Isgutdysbiosisassociatedwiththepoorreactivitytoursodeoxycholicacidaswellasthelong-termprognosisinpatientswithprimarybiliarycholangitis? M.Furukawa,K.Moriya,T.Namisaki,K.Seki,S.Saikawa,S.Sato,Y.Sawada,H.Takaya,K.Kaji,Y.Okura,N.Shimozato,H.Kawaratani,M.Kitade, T.Akahane,A.Mitoro,J.Yamao,H.Yoshiji(Nara,JP)

127. Trans-fattyacid-richdietpromoteslivertumorigenesisinHCVcoreprotein-expressingtransgenicmice N.Tanaka,X.Hu,X.Wang,T.Kimura,K.Moriya,K.Koike,T.Aoyama(Matsumoto,Tokyo,JP)

128.*UpregulatedexpressionofPD-1/PD-L1onperipheralTandBcellscorrelateswiththeseverityofalcoholicliverdiseaseinfemales B.Kasztelan-Szczerbinska,K.Adamczyk,A.Surdacka,H.Cichoz-Lach, J.Rolinski,A.Michalak,J.Onikijuk,B.Zygo,M.Szczerbinski(Lublin,Warsaw,PL)

129.Novelbiomarkersforpredictingtheoccurrenceofdenovonon-alcoholicfattyliverdiseaseinlivertransplantrecipients L.S.Gheorghe,C.Ester,S.Iacob,R.Cerban,G.Constantin,L.Paslaru, C.Grancea,S.Ruta(Bucharest,RO)

130.Real-lifeimprovementofHCV-GT1decompensatedlivercirrhosisfollowingtherapywithsofosbuvir/ledipasvir L.S.Gheorghe,S.Iacob,C.Mihai,I.Girleanu,I.Ciortescu,L.Sandulescu,C.Preda,M.Diculescu,C.CijevschiPrelipcean,S.M.Bataga,V.Drug, A.Plesa,C.Cojocariu,G.Stefanescu,A.M.Singeap,C.Pietrareanu, I.Simionov,R.Vadan,I.Pirvulescu,R.Iacob,C.Gheorghe,R.Sirli, I.Sporea,P.Mitrut,C.Stanciu,A.Trifan(Bucharest,Iasi,Craiova,TirguMures,Timisoara,RO)

131.*EffectsofaDPP4inhibitoronprogressionofNASH-relatedHCCwithalterationsinp62/Keap1/Nrf2pathwayinamousemodel T.Kawaguchi,D.Nakano,H.Koga,T.Torimura(Kurume,JP)

132.Differentialdiagnosisofunclearcasesofprimarysclerosingcholangitis:Contributionofnext-generationvideo-digitalcholangioscopy S.Budzinskiy,E.Fedorov,D.Bakhtiozina,S.Shapovaliants,E.Platonova(Moscow,RU)

133.*Westerndietduringconceptionandlactationdevelopprogressionofmurinenon-alcoholicsteatohepatitis K.Tomita,S.Ibrahim,Y.Ueno(Yamagata,JP;Rochester,US)


23

134.*Lipoproteinlipaseinhepaticstellatecellsexaggeratesliverfibrosisinnon-alcoholicsteatohepatitisinmice N.Sugihara,K.Tomita,H.Furuhashi,K.Inaba,K.Horiuchi,Y.Hanawa, A.Wada,T.Takajo,N.Shibuya,M.Higashiyama,C.Kurihara,Y.Okada, C.Watanabe,S.Komoto,R.Hokari(Tokorozawa,JP)

135.Porphyran,afunctionalingredientofJapanese‚‘Nori‘‘,improvesnon-alcoholicfattyliverviamodifiedceramidesynthesispathways M.Watanabe,Y.Takashina,K.Tanaka,S.Fukuda,K.Tsubota,K.Ishihara(Fujisawa,Tsuruoka,Tokyo,Yokohama,JP)

136.Increasedfrequencyofmyeloid-derivedsuppressorcellsinpatientswithnon-alcoholicfattyliverdisease M.Abe,Y.Nakamura,T.Miyake,A.Yukimoto,Y.Imai,Y.Koizumi,T.Watanabe,O.Yoshida,M.Hirooka,Y.Hiasa(Ehime,JP)

137. ThenovelcutoffpointsfortheFIB4indexcategorizedbyageincreasethediagnosticaccuracyinNAFLD:Amulticenterstudy Y.Sumida,H.Ishiba,S.Tanaka,H.Hyogo,M.Ono,H.Fujii,Y.Suzuki, M.Yoneda,T.Kawaguchi,A.Nakajima,Y.Eguchi,K.Chayama,T.Okanoue,Y.Itoh(Nagakute,JP)

138.STAT3–AnovelPDC-E2interactingpartnerinhumancholangiocytes E.Kilanczyk,J.M.Banales,P.Milkiewicz,M.Milkiewicz(Szczecin,Warsaw,PL;SanSebastian,ES)

139.ClinicalfeaturesandstabilityofhepatitisBsurfaceantigenseroclearanceinuntreatedandnucleos(t)ideanaloguetreatedpatients Y.Kim,H.W.Lee,J.I.Lee,K.S.Lee(Seoul,KR)

140.TheoccurrencerateofclinicaleventsinJapanesePSCcohort–Apotentialroleassurrogateendpointsforclinicaltrials M.Sakurai,T.Arizumi,A.Tanaka,S.Tazuma,T.Nakazawa,H.Isayama, T.Tsuyuguchi,K.Inui,H.Takikawa;JapanPSCStudyGroup(Tokyo,Hiroshima,Nagoya,Chiba,JP)

141. Elevatedhepaticironoverloadobtainedbymagneticresonanceimagingreflectshepaticinflammationandballooninginpatientswithnon-alcoholicfattyliverdisease K.Imajo,K.Suzuki,Y.Honda,Y.Ogawa,M.Yoneda,T.Kessoku,S.Saito,A.Nakajima(Yokohama,JP)

142. Exercisetrainingmediateslipidinfiltrationofskeletalmuscleandimprovesnon-alcoholicfattyliverdisease H.Takahashi,Y.Kitajima,Y.Kubotsu,K.Tanaka,K.Anzai,Y.Eguchi(Saga,JP)

143.*Technetium-99m-GSAscintigraphyobtainedwithinthreedaysofadmissionasanearlypredictorofoutcomeinacuteliverfailureandsevereacutehepatitis Y.Suzuki,K.Kakisaka,T.Sato,R.Mikami,T.Sasaki,Y.Takikawa(Morioka,JP)


24

144.Immuneresponsetotumor-associatedantigensandimmunecellprofilesinNASH-relatedhepatocellularcarcinoma T.Seike,E.Mizukoshi,S.Kaneko(Kanazawa,JP)

145.Next-generationsequencinginwhole-genomecharacteristicsofhepatitisBvirusinKorean H.W.Lee,J.H.Lee,H.Y.Chang,Y.Kim,J.I.Lee,K.S.Lee(Seoul,Hwasun,KR)

146.Multidisciplinaryteamapproachtohepatocellularcarcinomamanagement:Threeyear-studyinalivertransplantcenterfromRomania R.Cerban,A.Croitoru,I.Popescu,R.Dumitru,M.Grasu,S.Iacob,C.Ester,M.Lita,L.S.Gheorghe,C.Gheorghe(Bucharest,RO)

147. ExploringviralfactorsassociatedwithHCCoccurrence/recurrenceafterantiviraltherapythroughHCVfull-openreadingframeanalysis S.Maekawa,M.Sato,Y.Suzuki,M.Muraoka,S.Matsuda,A.Tatsumi, Y.Nakayama,T.Inoue,M.Sakamoto,N.Enomoto(Yamanashi,JP)

148.AretheGlobeandUK-PBCscoresalsoeffectiveforpredictingriskinpatientstreatedwithbezafibrateinadditiontoursodeoxycholicacid? AvalidationstudyinJapan K.Matsumoto,A.Tanaka,A.Honda,A.Komori,M.Abe,M.Inao,T.Namisaki,N.Hashimoto,K.Kawata,A.Takahashi,M.Ninomiya,J.H.Kang,M.Arakawa,S.Yamagiwa,S.Joshita,T.Umemura,K.Sato,A.Kaneko,K.Kikuchi, J.Itakura,T.Nomura,K.Kakisaka,H.Fujii,N.Kawada,Y.Takikawa, T.Masaki,H.Ohira,S.Mochida,H.Yoshiji,Y.Matsuzaki,H.Takikawa;JapanPBCStudyGroup(Tokyo,Ibaraki,Nagasaki,Ehime,Saitama,Kashihara,Hamamatsu,Fukushima,Sendai,Sapporo,Oita,Niigata,Matsumoto,Maebashi,Suita,Kawasaki,Musashino,Kagawa,Morioka,Osaka,JP)

149.DiscoveryofanoveltherapeuticagenttargetingHBx-DDB1interactionforHBVcure K.Sekiba,M.Otsuka,K.Koike(Tokyo,JP)

150.Indirectindicesofliverfibrosisinthecourseofalcoholicliverdisease,non-alcoholicfattyliverdiseaseandprimarybiliarycholangitis A.Michalak,H.Cichoz-Lach,M.Guz,M.Cybulski,B.Kasztelan-Szczerbinska(Lublin,PL)

151. EffectsofLippiacitriodorainhigh-fatdiet-fedmice:NAFLDandalteredintestinalpermeability C.Galvez-Lorente,J.Garcia-Garcia,P.Diez-Echave,T.Vezza,L.Hidalgo-Garcia,J.Garrido-Mesa,F.J.Leyva-Jimenez,A.Segura-Carretero, M.E.Rodriguez-Cabezas,J.Galvez(Granada,Pamplona,ES)

152.RiskfactorsassociatedwithhypophosphatemiainchronichepatitisBpatientstreatedwithtenofovirdisoproxilfumarate K.I.Seo,B.C.Yun,B.H.Han,S.U.Lee,E.T.Park(Busan,KR)


25

153.Ispatient-reportedoutcomeimprovedbynalfurafinehydrochlorideinpatientswithprimarybiliarycholangitisandrefractorypruritus?Apost-marketing,single-arm,prospectivestudy R.Miura,M.Yagi,A.Tanaka,T.Namisaki,A.Takahashi,M.Abe,A.Honda,Y.Matsuzaki,H.Ohira,H.Yoshiji,H.Takikawa;JapanPBCStudyGroup(Tokyo,Kashihara,Fukushima,Ehime,Ibaraki,JP)

154.AlcoholconsumptionisassociatedwiththeremissionoffattyliverinJapanesemen:Aprospectivestudy A.Moriya,Y.Iwasaki,E.Kayashima,T.Mitsumune,H.Taniguchi,F.Ikeda,M.Ando(Kanonji,Okayama,Tottori,JP)

155.Posaconazole-associatedhyperbilirubinemiainapatientwithacutemyeloidleukemiafollowingchemotherapy:Atoxicityworthconsidering Z.Song,Y.Pan,R.Zhao,H.Jing,F.Dong(Beijing,CN)

156.DevelopmentofhepatocellularcarcinomainpatientsinfectedwithhepatitisBvirusgenotypeBorCinJapan H.Haga,T.Saito,K.Okumoto,K.Tomita,K.Mizuno,T.Nishina,Y.Ueno(Yamagata,JP)

157. Iszinceffectiveforthepredictionandthetreatmentofhepaticfibrosisinpatientswithautoimmunehepatitis? K.Moriya,T.Namisaki,M.Furukawa,S.Sato,K.Kitagawa,H.Kawaratani,K.Kaji,M.Kitade,T.Akahane,A.Mitoro,H.Yoshiji(Nara,JP)

158.*Carbonmonoxideenrichedredbloodcellsimprovemurinemodelsofnon-alcoholicsteatohepatitisthroughitsmultifacetedhepatoprotectiveactions T.Maruyama,H.Yanagisawa,H.Maeda,H.Watanabe,M.Tanaka,Y.Sasaki(Kumamoto,JP)

159.Isoliqiritigenin,naturalflavonoidusedorientalherbalmedicine,regulateimprovednon-alcoholicfattyliverbychangingmacrophage Y.Yokoyama,H.Taoka,K.Yashiro,T.Tanon,A.Nakamura,N.Kitamura, A.Honda,K.Tsubota,M.Watanabe(Fujisawa,Ibaraki,Tokyo,JP)

160.Asperuloside,theextractionofTochu-teapreventsfattyliverandnon-alcoholicsteatohepatitisdiseasethroughimprovingliverfunction A.Nakamura,T.Hirata,T.Ueda,A.Honda,N.Kitamura,Y.Yokoyama, M.Watanabe(Fujisawa,Osaka,Ibaraki,JP)

161. L-carnitinereducesmusclemasslossinpatientswithlivercirrhosis A.Hiramatsu,H.Aikata,Y.Inagaki,K.Morio,H.Fujino,T.Nakahara, E.Murakami,T.Kawaoka,D.Miki,M.Tsuge,M.Imamura,K.Chayama(Hiroshima,JP)

162.LinkerphosphorylationofSmad3promotesfibro-carcinogenesisinnon-alcoholicsteatohepatitisofhepatocellularcarcinoma K.Suwa,T.Yamaguchi,K.Yoshida,M.Murata,K.Matsuzaki,K.Okazaki(Osaka,JP)


26

163.Nicotinamideameliorateshepaticsteatosisviasirtuinactivation M.Nakamuta,K.Ohe,K.Tababe,N.Ookubo,N.Togawa,M.Enjoji(Fukuoka,Tokyo,JP)

164.EffectsofaSGLT2inhibitorongrowthandmetabolismsonhepatocellularcarcinoma D.Nakano,T.Kawaguchi,H.Iwamoto,M.Hayakawa,H.Koga,T.Torimura(Kurume,JP)

165.ALAimprovesmitochondrialfunctionandpreventslipidaccumulation,oxidativestress,anddiet-inducedsteatohepatitis N.Kitamura,Y.Yokoyama,A.Nakamura,M.Watanabe(Fujisawa,JP)

166.AcuteliverfailureduetoHBVreactivationassociatedwithimmunosuppressiveoranticancertherapiesinJapan(2010–2016) N.Nakayama,M.Nakao,Y.Uchida,H.Tsubouchi,H.Takikawa,S.Mochida(Moroyama,Kagoshima,Tokyo,JP)

167. AccuracyofselectedCCLandCXCLchemokinesintheassessmentofpatientswithalcoholicliverdisease M.Szczerbinski,B.Kasztelan-Szczerbinska,J.Onikijuk,A.Surdacka, H.Cichoz-Lach,J.Rolinski,K.Adamczyk,A.Michalak,B.Zygo,B.Wilczynska(Lublin,Warsaw,PL)

168.*Combinationeffectofcanagliflozinandexercisetraininginnon-alcoholicfattyliverdisease K.Tanaka,H.Takahashi,K.Anzai,Y.Eguchi(Saga,JP)

169.TheoptimalexerciseregimenforpatientswithNAFLD:Aerobicorresistanceexercise? T.Nishimura,T.Kawaguchi,R.Hashida,D.Nakano,N.Shiba,T.Torimura(Kurume,JP)

170. DPP-4inhibitorsuppressestheprogressionofhepatocellularcarcinomathroughactivationofchemotaxisofNKcellsinmice S.Nishina,A.Yamauchi,K.Sasaki,Y.Tomiyamai,Y.Hara,K.Hino(Kurashiki,JP)

171. Evaluationofballoonedhepatocytesasariskfactorforfutureprogressionoffibrosisinpatientswithnon-alcoholicfattyliverdisease K.Kakisaka,Y.Suzuki,Y.Fujiwara,T.Abe,H.Kuroda,Y.Takikawa(Morioka,JP)

172. AllogenictransplantationofMUSEcelladministrationamelioratesliverfunctioninpigmodelsofchronicliverinjury T.Nishina,S.Wakao,H.Haga,K.Okumoto,K.Tomita,K.Mizuno,T.Saito,M.Dezawa,Y.Ueno(Yamagata,Sendai,JP)

173.*ClinicalmanagementofprimarysclerosingcholangitisinJapan2017 S.Tazuma,T.Nakazawa,K.Notohara,H.Isayama,T.Tsuyuguchi, M.Serikawa,T.Mori,A.Tanaka,H.Takikawa(Hiroshima,Tokyo,JP)


27

174. Amulticentreprospectivestudy:Ballooningbiomarkerinpatientswithnon-alcoholicfattyliverdisease Y.Ogawa,Y.Honda,T.Kessoku,K.Imajo,M.Yoneda,T.Andou,H.Kamiguchi,Y.Amano,S.Ogawa,T.Nakahara,H.Takahashi,H.Hyogo,S.Saito, K.Chayama,M.Kage,Y.Eguchi,A.Nakajima(Yokohama,Hiroshima,Saga,Kurume,JP)

175. Systemicprofileofneutrophil-derivedmediatorsanditsassociationwiththeseverityofalcoholicliverdisease B.Kasztelan-Szczerbinska,B.Zygo,A.Surdacka,H.Cichoz-Lach,J.Rolinski,K.Adamczyk,A.Michalak,J.Onikijuk,M.Szczerbinski,B.Wilczynska(Lublin,Warsaw,PL)

176.*Characteristicsandriskfactorsoffattyliverdiseasedevelopmentandnon-alcoholicsteatohepatitisrecurrencefollowinglivertransplantation K.Tokodai,A.Karadagi,F.Kjaernet,A.Romano,B.G.Ericzon,G.Nowak(Stockholm,SE)

177. PromisingantiviralcombinationtherapytargetingHBVeradicationwithanovelcompoundderivedfromspice K.Okushin,H.Fujinaga,T.Tsutsumi,K.Ikeuchi,A.Kado,K.Enooku, H.Yotsuyanagi,K.Koike,K.Moriya(Tokyo,JP)

178.*RelevanceofFXR-p62/SQSTM1pathwayforsurvivalandprotectionofmousehepatocytesandliverwithsteatosis M.Ozaki,S.Haga(Sapporo,JP)

179. EffectivebiomarkersforadvancefibrosisNASHandreflectbiomarkersaschangesofliverfibrosiswithNASH M.Kawanaka,K.Nishino,K.Ishii,T.Tanikawa,N.Urata,J.Nakamura, M.Suehiro,T.Sasai,K.Haruma,H.Kawamoto(Okayama,JP)

180.Beneficialeffectsofagomelatineonobesityassociatedliverinflammationinmice M.E.Rodriguez-Cabezas,T.Vezza,P.Diez-Echave,L.Hidalgo-Garcia, J.Garrido-Mesa,M.M.Martinez-Lao,J.Galvez(Granada,ES)

*=PostersofDistinction


28

List of Speakers, Moderators and Scientific Organizers

Prof. Dr. Matthieu AllezService de GastroentérologieHôpital Saint-Louis1, avenue Claude Vellefaux75010 ParisFrancematthieu .allez@aphp .fr

Prof. Dr. Akira AndohDepartment of MedicineShiga University of Medical Science Seta-Tsukinowa, Otsu Shiga 520-2192Japanandoh@belle .shiga-med .ac .jp

Dr. Charles N. BernsteinDepartment of GastroenterologyUniversity of Manitoba804 F-175 McDermot AvenueWinnipeg, MB R3E 3P4Canadacharles .bernstein@med .umanitoba .ca

Prof. Dr. Henry L. Y. ChanDepartment of Medicine and TherapeuticsPrince of Wales Hospital9/F Lui Che Woo Clinical Sciences Building30-32 Ngan Shing StreetShatin, Hong KongHong Konghlychan@cuhk .edu .hk

Dr. Eugene B. ChangProfessor of MedicineKnapp Center for Biomedical DiscoveryUniversity of Chicago900 East 57th StreetChicago, IL 60637USAechang@medicine .bsd .uchicago .edu

Prof. Dr. Emad M. El-OmarSt . George and Sutherland Clinical SchoolUniversity of New South WalesLevel 2 Clinical Sciences (WR Pitney) BuildingSt . George HospitalShort Street, KogarahSydney, NSW 2217Australia e .el-omar@unsw .edu .au

Prof. Dr. Marc FerranteGastro-entérologieUniversity Hospital LeuvenHerestraat 493000 LeuvenBelgiummarc .ferrante@uz .kuleuven .ac .be

Prof. Dr. Shinji Fukuda Institute for Advanced BiosciencesKeio University246-2 Mizukami, Kakuganji, Tsuruoka Yamagata 997-0052 Japansfukuda@sfc .keio .ac .jp

Daniel Graham, Ph.D. Broad Institute415 Main StreetCambridge, MA 02142USAdgraham@broadinstitute .org

Dr. Hideaki HamanoDivision of Medical InformaticsDepartment of Internal Medicine/ GastroenterologyShinshu University Hospital3-1-1 Asahi, Matsumoto-shiNagano 390-8621Japanhidehama@shinshu-u .ac .jp


29

Prof. Dr. Eiji HaraDepartment of Molecular MicrobiologyResearch Institute for Microbial DiseasesOsaka University3-1 Yamadaoka, Suita-shi Osaka 565-0871 Japaneiji .hara@jfcr .or .jp

Dr. Keisuke HataDepartment of Surgical Oncology Graduate School of Medicine The University of Tokyo 7-3-1 Hongo Bunkyo-ku Tokyo 113-8655 Japan khata-tky@umin .ac .jp

Prof. Dr. Toshifumi HibiDepartment of Internal MedicineKitaso Institute HospitalKitaso University5-9-1 Shirokane, Minato-kuTokyo 108-8642Japanthibi@insti .kitasato-u .ac .jp

Prof. Dr. Tadakazu Hisamatsu3rd Department of Internal MedicineSchool of MedicineKyorin University 6-20-2 Shinkawa, MitakaTokyo 181-8611Japanthisamatsu@ks .kyorin-u .ac .jp

Prof. Dr. Frank HoentjenGastroenterology Institute for Molecular Life SciencesRoute 455 Geert Grooteplein 10 Nijmegen 6525 GA The Netherlandsfrank .hoentjen@radboudumc .nl

Dr. Michio ImawariInstitute of Gastrointestinal and Liver DiseasesShin-yurigaoka General Hospital255 Furusawa Tsuko, Asao-kuKanagawa 215-0026Japanimawari@me .com

Dr. Tatsuya KantoThe Research Center for Hepatitis and ImmunologyNational Center for Global Health and Medicine1-7-1 KohnodaiIchikawa Chiba, 272-8516 Japankantot@hospk .ncgm .go .jp

Prof. Dr. Tom H. KarlsenDepartment of Transplantation Medicine Division of Surgery, Inflammatory Diseases and Transplantation Oslo University Hospital Rikshospitalet Pb 4950 Nydalen0424 OsloNorwaytomhk@ulrik .uio .no

Dr. Taku Kobayashi Center for Advanced IBD Research and Treatment Kitasato Institute HospitalKitasato University5-9-1 Shirokane, Minato-ku Tokyo 108-8642Japankobataku@insti .kitasato-u .ac .jp

Prof. Dr. Kazuhiko KoikeDepartment of GastroenterologyGraduate School of MedicineThe University of Tokyo7-3-1 Hongo Bunkyo-kuTokyo 113-8655Japankkoike-tky@umin .ac .jp


30

Rohit Loomba, M.D.Professor of MedicineDivision of GastroenterologyUniversity of California, San Diego9452 Medical Center Dr . MC #0887La Jolla, CA 92037-0887USAroloomba@ucsd .edu

Uma Mahadevan, M.D.Professor of MedicineUniversity of California, San Francisco1701 Divisadero Street #120San Francisco, CA 94115USAuma .mahadevan@ucsf .edu

Prof. Dr. Takayuki MatsumotoDepartment of Internal MedicineDivision of Gastroenterology Iwate Medical UniversitySchool of Medicine19-1 Uchimaru Morioka Iwate 020-8505Japantmatsumo@iwate-med .ac .jp

Prof. Dr. Atsushi NakajimaDepartment of Gastroenterology and HepatologyYokohama City University School of Medicine 3-9 Fukuura, Kanazawa-ku, Yokohama Kanagawa 236Japannakajima-tky@umin .ac .jp

Prof. Dr. Hiroshi NakaseDepartment of Gastroenterology and HepatologySchool of MedicineSapporo Medical University S-1, W-16, Chuo-kuSapporo 060-8543 Japanhiropynakase@gmail .com

Prof. Dr. Markus F. NeurathMedizinische Klinik IUniversitätsklinikum ErlangenUlmenweg 1891054 ErlangenGermanymarkus .neurath@uk-erlangen .de

Prof. Dr. Siew C. NgDepartment of Medicine and Therapeutics Division of Gastroenterology and Hepatology State Key Laboratory of Digestive DiseaseFaculty of MedicineThe Chinese University of Hong KongNgan Shing Street, Shatin, NTHong Kongsiewchienng@cuhk .edu .hk

Dr. Hiroshi OhnoLaboratory for Intestinal EcosystemRIKEN Center for Integrative Medical Sciences (IMS)Intestinal Microbiota ProjectKanagawa Institute of Industrial Science and Technology1-7-22 Suehiro, Tsurumi, YokohamaKanagawa 230-0045Japanhiroshi .ohno@riken .jp

Prof. Dr. Hiroaki OkamotoDivision of VirologyDepartment of Infection and ImmunityJichi Medical University School of Medicine3311-1 Yakushiji, Shimotsuke-shi Tochigi 329-0498Japanhokamoto@jichi .ac .jp

Dr. Takeshi OkanoueDepartment of Gastroenterology and HepatologySaiseikai Suita Hospital1-2 Kawazono SuitaOsaka 564-0013Japanokanoue@suita .saiseikai .or .jp


31

Prof. Dr. Kazuichi OkazakiDepartment of Gastroenterology and HepatologyKansai Medical University Hospital2-5-1, Sinmachi, HirakataOsaka 573-1191Japanokazaki@hirakata .kmu .ac .jp

Prof. Dr. Jean-Michel PawlotskyNational Reference Center for Viral Hepatitis B, C and D Department of Virology Hôpital Henri MondorUniversité Paris-Est51 avenue du Marechal de Lattre de Tassigny94010 CreteilFrancejean-michel .pawlotsky@hmn .aphp .fr

Prof. Dr. Dr. Gerhard RoglerKlinik für Gastroenterologie& HepatologieUniversitätsspital ZürichRämistr . 1008091 ZürichSwitzerlandgerhard .rogler@usz .ch

Prof. Dr. Stefan SchreiberKlinik für Innere Medizin IUniversitätsklinikumSchleswig-Holstein, Campus KielArnold-Heller-Str . 3 (Haus 6)24105 KielGermanys .schreiber@mucosa .de

Dr. Christian SelingerDepartment of GastroenterologyLeeds Teaching Hospitals NHS TrustSt James University HospitalBexley WingBeckett StreetLeeds LS9 7TFGreat Britainchristian .selinger@web .de

Prof. Dr. Ala ShararaDepartment of Internal MedicineDivision of Gastroenterology American University of Beirut Medical CenterPO Box 11-0236Riad El Solh 11072020 Beirut Lebanonala .sharara@aub .edu .lb

Dario Sorrentino, M.D. Professor of MedicineDivision of Gastroenterology / Inflammatory Bowel DiseasesVirginia Tech - Carilion School of Medicine3 Riverside CircleRoanoke, VA 24016USAdrsorrentino@carilionclinic .org

Prof. Dr. Yasuo SuzukiDepartment of Internal Medicine Sakura Medical CenterToho University564-1, Shimoshizu, SakuraChiba 285-8741Japanyasuo-suzuki@sakura .med .toho-u .ac .jp

Prof. Dr. Kiyoshi TakedaLaboratory of Immune RegulationDepartment of Microbiology and ImmunologyGraduate School of MedicineWPI Immunology Frontier Research Center (IFReC)Osaka University2-2 Yamada-oka, SuitaOsaka 565-0871Japanktakeda@ongene .med .osaka-u .ac .jp

Prof. Dr. Hajime TakikawaDepartment of MedicineTeikyo University School of MedicineKaga 2-11-1, Itabashi-kuTokyo 173-8605Japantakikawa@med .teikyo-u .ac .jp


32

Prof. Dr. Atsushi TanakaDepartment of MedicineSchool of MedicineTeikyo University2-11-1, Kaga, Itabashi-ku Tokyo 173-8605Japana-tanaka@med .teikyo-u .ac .jp

Prof. Dr. Herbert TilgKlinik für Innere Medizin IUniversitätsklinik InnsbruckAnichstr . 356020 InnsbruckAustriaherbert .tilg@i-med .ac .at

Prof. Dr. Yoshiyuki UenoDepartment of GastroenterologyYamagata University Faculty of Medicine2-2-2 Iida-Nishi, YamagataYamagata 990-9585Japany-ueno@med .id .yamagata-u .ac .jp

Prof. Dr. C. Janneke van der WoudeAfd . GastroenterologieErasmus Medical Center‚s-Gravendijkwal 2303015 CE RotterdamThe Netherlandsc .vanderwoude@erasmusmc .nl

Prof. Dr. Mamoru WatanabeDepartment of Gastroenterologyand HepatologyTokyo Medical & Dental University1-5-45, Yushima, Bunkyo-kuTokyo 113-8519Japanmamoru .gast@tmd .ac .jp

Dr. Zobair M. YounossiDepartment of MedicineCenter for Liver DiseasesInova Fairfax Hospital3300 Gallows Rd Falls Church, VA 22042USAzobair .younossi@inova .org


33

Congress OfficeDuring Symposium 212

Congress Office Telephone: +49-175-7795-327

Opening Hours:Thursday, September 6, 2018 16 .00 – 21 .00 hFriday, September 7, 2018 7 .30 – 17 .30 hSaturday, September 8, 2018 8 .00 – 17 .00 h

Kyoto Hotel OkuraKawaramachi-Oike,Nakagyo-kuKyoto 604-8558Japan

Admission to Scientific ProgramFor admission to scientific events your name badge should be clearly visible .

Conflicts of InterestMembers of the scientific committee declare the following potential conflicts of interest:Toshifumi Hibi: Mitsubishi-Tanabe Pharma, Abbvie GK, Mochida Pharmaceutical, Miyarisan Pharmaceutical, JIMRO, Zeria Pharmaceutical, Nippon Kayaku, Takeda Pharmaceutical, EA Pharma, Janssen, Eli Lilly, Pfizer, Otsuka Holdings CO . Ltd ., Kyorin Pharmaceutical, Gilead Sciences, Kissei Pharmaceutical, Ferring Pharmaceutical; Tadakazu Hisamatsu: Mitsubishi Tanabe Pharma Corporation, EA Pharma, AbbVie GK, JIMRO, Asahi Kasei Kraray Medical Co . Ltd ., Zeria Pharmaceutical, Daiichi-Sankyo, Kuraray Pharmaceutical, Nichilko Pharmaceutical, Nippon Kayaku, Astellas Pharma, Takeda Pharmaceutical, Pfizer, Mochida Pharmaceutical, Celgene, Janssen; Michio Imawari: Shionogi&Co . Ltd, Japan Bio Products, EA Pharma; Gerhard Rogler: Abbot, Abbvie, Ardeypharm, Augurix, Calypso, Essex/MSD, Falk Pharma, Flamentera, Novartis, Roche, Takeda, Tillots, UCB, Zeller, Boehringer, Ferring, Fisher, Genentech, Pfizer, Phadia, Vifor, Vital Solutions, Astra Zeneca; Herbert Tilg declares no Conflicts of Interests .

SponsoringEA Pharma is the official Co-Sponsor for the Symposium 212 . Nevertheless all costs for Catering (Coffee- and Lunch Breaks, Welcome Dinner, Flying Buffet and Speakers Dinner) will be covered 100% by Falk Foundation e .V . exclusively .


34

AirportKyoto is located approximately 400 km southwest of Tokyo and approximately 40 km from Osaka . It is easily accessible from different cities within Japan .

From OsakaKansai International Airport The airport is connected to Kyoto by the “Haruka Limited Express” train . The train leaves every 30 minutes and the journey lasts approximately 75 minutes .The airport also offers a shuttle bus, which takes approximately 1 .5–2 hours .(www .kansai-airport .or .jp)

From TokyoHaneda International Airport Take the subway to Shinagawa train station . Change there onto the “Shikansen” train to Kyoto . The journey lasts approximately 2 .5–3 hours .(www .tokyo-airport-bldg .co .jp)

From Kyoto train station to Kyoto Hotel OkuraTrains depart every 6 minutes and take approximately 15 minutes . Please transfer at Karasuma-Oike station . Kyoto -> Karasuma-Oike -> Kyotoshiyakusyo-mae

For more detailed information or an organized transfer please check the hotel website http://okura.kyotohotel.co.jp/english/about/access/ or contact a travel agency . You can also find information about different possibilities on this website: http://kyoto.travel/en/traveller_kit/accessinfo_city


Program

P212

1-7

/201

8/6

00

Stü

Organized by:

FALK FOUNDATION e.V.Leinenweberstr. 579108 FreiburgGermany

Congress DepartmentTel.: +49–761–1514–125Fax: +49–761–1514–359E-Mail: symposia@falk-foundation-symposia.orgwww.falk-foundation-symposia.org

Symposium 212



CME credits12

Awardedwith

17811_Falk_Kyoto_Symp_212_Prog_UG.indd 1 30.07.18 10:32

September 7–8, 2018 Kyoto Hotel Okura Kyoto, Japan6. The prevalence of liver, biliary tract and...

Documents

Transcript of September 7–8, 2018 Kyoto Hotel Okura Kyoto, Japan6. The prevalence of liver, biliary tract and...